Skip to main content

InvestorNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Expands Product Portfolio to Launch Evolve(TM) Soft Bait

SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, today announced the launch of Evolve(TM) Soft Bait, a solution designed to reduce fertility in rats. According to the announcement, the minimum-risk solution is the first and only soft bait developed to control pest populations using a breakthrough technology that targets the rat population where it starts by restricting fertility through nonlethal methods. “Evolve(TM) was developed to offer customers a soft bait product that has similar efficacy to ContraPest(R), but in a format that is easier to deploy and predominantly used in the rodenticide market,” said Joel Fruendt, SenesTech’s president and CEO. “Evolve(TM) is ideal for use by professionals in a format they can use daily in their integrated pest management programs, as well as being available to the consumer market through e-commerce or big box stores, which will expand our reach to a broader array of customers. The addition of Evolve(TM) to our portfolio of fertility control products will geometrically increase our addressable market.”

To view the full press release, visit https://ibn.fm/FG7rL

About SenesTech Inc.

SenesTech is an expert in animal fertility control. The company’s passion is to create a healthy environment by better controlling animal pest populations. Keeping an inescapable truth in mind—that two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year—SenesTech invented ContraPest(R), the only U.S. EPA registered contraceptive for male and female rats, and Evolve(TM) minimum risk soft bait. Its products fit seamlessly into all integrated pest management programs, greatly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be effective and sustainable. The company is committed to improving the health of the world by humanely managing animal populations through fertility control. For more information about the company, visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.